Clinical Research of 125I Seeds Implantation Combined with Chemotherapy in the Treatment of Middle-Late Stage Non-Small Cell Lung Cancer

FANG Yong,NI Xudong,WANG Jian
DOI: https://doi.org/10.3969/j.issn.1008-6358.2013.02.008
2013-01-01
Abstract:Objective:To investigate the technological feasibility and efficacy of radioactive iodine 125 seeds implantation combined with chemotherapy in the treatment of middle-late stage NSCLC.Methods:A total of 38 patients with middle-late stage NSCLC were treated by 125I seeds implantation combined with chemotherapy during December 2006 to December 2009.Before the operation,the simulated dose distribution,the amount of iodine and the radiation activity were calculated by treatment planning system(TPS).The seeds distribution plan was also established,and the implantation position was artificially modified during the operation.Quality assurance was performed by post-operational CT scan.Results: The distribution of implanted iodine in 82.4% patients(32/38) was in accordance with simulated dose distribution.A total of 1046 iodine was implanted in all patients with an average of 27.5 in each lesion.No death was reported in perioperative period.All patients have been followed-up for an average period of 16.3 months.Among them,14 patients(36.8%) were in complete remission,21(55.3 %) cases were in partial remission,and 3 cases were stabilized(7.9 %).The total effective rate was 92.1 %.The survival rates at 1 year and 2 years were 81.2%(31/38) and 66.7%(18/27),respectively.Neither radiation pneumonia nor iodine miss translocation or elimination from the body occurred.Conclusions: 125I seeds implantation combined with chemotherapy have good efficacy with low complication rate in middle-late stage NSCLC patients.
What problem does this paper attempt to address?